Ph 1 ADI-PEG 20 Plus Doxorubicin; Patients With HER2 Negative Metastatic Breast Cancer
Status:
Completed
Trial end date:
2016-04-01
Target enrollment:
Participant gender:
Summary
Certain cancers require the amino acid arginine. Arginine deiminase (ADI) is an enzyme from
microbes that degrade arginine. ADI has been formulated with polyethylene glycol, and has
been used to treat patients that have cancers that require arginine. In this study, ADI will
be combined with the well known chemotherapy Doxorubicin and the safety and potential
efficacy of this combination will be explored in patients with HER2 Negative Metastatic
Breast Cancer.